Clinical Trial Update: Study Using CP-751,871 In Patients With Stage IV Colorectal Cancer That Has Not Responded To Previous Anti-Cancer Treatments [Phase 2]

View source ↗

Summary

Pfizer conducted a Phase 2 trial of CP-751,871 (figitumumab) in stage IV colorectal cancer patients who had progressed after prior therapies; the study complete…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• CP-751,871 (dalotuzumab)

Snippet

Sponsor: Pfizer | Conditions: Colorectal Neoplasm | Phase 2 | Status: COMPLETED | Results posted: 2013-05-09